FDA Brief

Warning letters Food

FDA warning letter to

APG SEVEN, INC

High riskIssued Apr 18, 2024Posted May 7, 2024Division of Human and Animal Food Operations East IV

FDA warned APG Seven that its supplement labels claim to treat cancer, diabetes and other diseases, making them unapproved new drugs.

What happened

FDA bought samples and labeling of the dietary supplements BioMoringa and BioDiabetin through the phone number on the company's website, and reviewed the website www.alpagi.net in April 2024 and the Facebook page "Productos naturales Alpagi." No inspection was done. FDA found that labels, website and a May 3, 2023 Facebook post claim the products cure, treat or prevent diseases such as cancer, diabetes, osteoporosis, lupus and fungal infections.

What FDA found

  1. The products are drugs because their labels and other labeling say they cure, treat or prevent disease.

    Section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)]
  2. The products are new drugs sold without FDA approval, and FDA has no scientific data showing they are safe and effective for these uses.

    Sections 201(p), 301(d) and 505(a) of the Act [21 U.S.C. 321(p), 331(d), 355(a)]
  3. BioMoringa, BioDiabetin, Maca Plus, Ginkgo Biloba and BioCell are misbranded because they lack adequate directions for use, since their claimed uses need a licensed practitioner's supervision.

    Section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]; 21 CFR 201.5
  4. Shipping these misbranded drugs across state lines is illegal.

    Section 301(a) of the Act [21 U.S.C. 331(a)]

What FDA wants

FDA asks the company to write back within 15 working days describing the specific steps taken to fix the violations and prevent them from recurring, with supporting documents. If the fixes cannot be finished in that time, the company must explain the delay and say when they will be done.

Who should pay attention

  • retailers and online sellers offering these supplement brands
  • supplement brands that use similar disease-treatment claims on labels or social media
  • consumers who buy products by phone from Spanish-language natural product sellers

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk